| 2026-08-31 | Press release | New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity |
| 2026-08-31 | Press release | Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases |
| 2026-08-28 | Press release | La FDA aprueba Mounjaro (tirzepatida) de Lilly para reducir el riesgo cardiovascular en adultos con diabetes tipo 2 |
| 2026-08-28 | Press release | FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes |
| 2026-08-26 | Press release | Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study |
| 2026-08-12 | Press release | Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market |
| 2026-08-05 | Press release | Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipe |
| 2026-08-05 | Press release | Press release · Q2 2026 · Aug 2026 |
| 2026-08-05 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-05 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-08-03 | Press release | Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12 |
| 2026-07-23 | Press release | Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improve · Q3 2026 |
| 2026-07-22 | Press release | Lilly confirms date and conference call for second-quarter 2026 financial results announcement |
| 2026-07-16 | Press release | Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions |
| 2026-07-09 | Press release | Lilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 bl |
| 2026-06-26 | Press release | Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocy |
| 2026-06-26 | Press release | Lilly launches “The Memory Radio Station” across Europe, inviting the public to visually reconstruct fading memories thr |
| 2026-06-25 | Press release | What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight |
| 2026-06-24 | Press release | Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders |
| 2026-06-06 | Deck | Lilly Investor Event at American Diabetes Association's (ADA) Presentation |
| 2026-05-20 | 8-K | Form 8-K, Item 8.01 |
| 2026-05-07 | 8-K | Form 8-K, Item 5.07 |
| 2026-04-30 | Press release | Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines |
| 2026-04-30 | 8-K | Form 8-K, Item 2.02 results |
| 2026-04-30 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-04-30 | Transcript | Q2 FY26 earnings call transcript |
| 2026-04-08 | Press release | Estimated First Quarter 2026 Acquired In-Process Research and Development (“IPR&D”) Charges |
| 2026-03-20 | Proxy | Definitive proxy statement |
| 2026-02-12 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-02-05 | Transcript | Q4 FY25 earnings call transcript |
| 2026-02-04 | Press release | Q4 2025 Lilly Press Release |
| 2026-02-04 | 8-K | Form 8-K, Item 2.02 results |
| 2025-11-21 | 8-K | Form 8-K, Item 5.02 |
| 2025-10-30 | Press release | Press release · Q3 2025 · Oct 2025 |
| 2025-10-30 | 8-K | Form 8-K, Item 2.02 results |
| 2025-10-30 | 10-Q | Form 10-Q for the quarter ended Sep 30 |
| 2025-08-20 | 8-K | Form 8-K, Item 8.01 |
| 2025-08-07 | Press release | Q2 2025 Lilly Press Release |
| 2025-08-07 | 8-K | Form 8-K, Item 2.02 results |
| 2025-08-07 | 10-Q | Form 10-Q for the quarter ended Jun 30 |